Evaluating Therapy With Encorafenib, Binimetinib, and Ribociclib in Melanoma

Video

Paola A. Ascierto, MD, medical oncologist, director of Melanoma Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori &ldquo;Fondazione G. Pascal,&rdquo; discusses results of a phase Ib/II dose-escalation study evaluating triple combination therapy with encorafenib, binimetiinib, and ribociclib (Kisquali) in patients with <em>BRAF V600</em> solid tumors and melanoma.

Paola A. Ascierto, MD, medical oncologist, director of Melanoma Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori &ldquo;Fondazione G. Pascal,&rdquo; discusses results of a phase Ib/II dose-escalation study evaluating triple combination therapy with encorafenib, binimetiinib, and ribociclib (Kisquali) in patients withBRAF V600solid tumors and melanoma.

Related Videos
Related Content